Table 1.
Demographic and clinical characteristics of patients taking enteric-coated aspirin.
| Item | Elderly group | Middle-aged group | P value (chi-squared test, Fisher's exact test, independent bk?>samples t-test, or Mann-Whitney's U-test) |
|---|---|---|---|
| n = 34 | n = 34 | ||
| Age (mean ± SD, years) | 65.5 ± 4.7 | 51.1 ± 5.4 | P < 0.001 |
| Male/female (n) | 22/12 | 27/7 | P = 0.280 |
| BMI (mean ± SD, kg/m2) | 25.5 ± 2.7 | 25.8 ± 3.2 | P = 0.711 |
| Aspirin using period (median (IQR), month) | 30.0 (12.0, 120.0) | 10.5 (2.0, 48.0) | P = 0.007 |
| Gastric Lanza score (median (IQR)) | 2.0 (2.0, 3.0) | 2.0 (1.0, 3.0) | P = 0.192 |
| Gastric larger erosions and/or ulcer (n (%)) | 7 (20.5) | 6 (17.6) | P = 1.000 |
| Gastric controlled examination time (mean ± SD, min) | 40.1 ± 7.4 | 42.4 ± 6.9 | P = 0.208 |
| Small-intestinal mucosal injury (at least one erosion and/or ulcer, n (%)) | 30 (88.2) | 15 (44.1) | P < 0.001 |
| Small-intestinal mucosal injury (larger erosions and/or ulcer, n (%)) | 11 (32.4) | 3 (8.8) | P = 0.033 |
| Small intestinal transit time (mean ± SD, min) | 314.5 ± 122.2 | 281.2 ± 86.5 | P = 0.199 |
| Digestive ulcer history (n (%)) | 3 (8.8) | 5 (14.7) | P = 0.709 |
| Hypertension (n (%)) | 23 (67.6) | 21 (61.8) | P = 0.800 |
| Diabetes mellitus (n (%)) | 14 (41.2) | 9 (26.5) | P = 0.305 |
| Coronary artery disease (n (%)) | 17 (50.0) | 12 (35.3) | P = 0.327 |
| Atrial fibrillation (n (%)) | 1 (2.9) | 1 (2.9) | P = 1.000 |
| Cerebral infarction (n (%)) | 3 (8.8) | 2 (5.9) | P = 1.000 |
| Hyperlipemia (n (%)) | 11 (32.4) | 13 (38.) | P = 0.800 |
| Positive FOBT (n (%)) | 3 (8.8%) | 2 (5.9%) | P = 1.000 |
| Haemoglobin (mean ± SD, g/L) | 140.7 ± 12.2 | 142.2 ± 10.7 | P = 0.385 |
| Urea (mean ± SD, mmol/L) | 5.5 ± 1.4 | 5.0 ± 1.4 | P = 0.236 |
SD, standard deviation; IQR, interquartile range; BMI, body mass index; FOBT: fecal occult blood test.